Omics and Neurobiology of Ageing

Centre for Healthy Brain Ageing (CHeBA) Research - Omics and Neurobiology of Ageing Group
CHeBA Omics and Neurobiology of Ageing is a collaborative group composed of staff and students from CHeBA, the Neuropsychiatric Institute (NPI) and the UNSW MW Analytical Centre Bioanalytical Mass Spectrometry Facility (BMSF).

About the Omics and Neurobiology of Ageing Research Group

This interdisciplinary group was formed to apply state-of-the-art analytical techniques to the advancement of biomarker and pathophysiology research in the areas of normal ageing, mild cognitive im¬pairment (MCI), Alzheimer’s Disease and other age-related neurodegenerative conditions. The group relies on a variety of mass spectrometry techniques for proteomics, lipidomics and metabolomics qualitative and quantitative analyses, physicochemical approaches to understanding protein-protein and protein-lipid/metabolite interactions and advanced molecular biology methods.

The group utilises human and murine brain cell cultures and postmortem tissue for understanding the brain and the ageing process. Our current work is committed to discovering the fundamental causes and possible treatments for age-related neurodegenerative disorders such as Alzheimer's, and neurodevelopmental diseases, as well as on genetic and metabolic changes that take place as organisms grow old. Working individually and collaboratively across labs and disciplines, we are uncovering novel insights that expand knowledge and promise to enhance quality of life for an ageing population.

We have state-of-the-art facilities to study the cellular and developmental biology of the brain. We have the expertise to culture, propagate, differentiate, engineer and transplant in animal models the neural stem cells from various sources including skin-derived neuroprogenitors and human mesenchymal stem cells from bone marrow. In addition, we have expertise in the derivation of new human embryonic stem cell lines including their clonal propagation.


  1. Identify potential biomarkers in plasma samples of control, MCI and AD subjects, which will discriminate normal ageing from changes associated with pathology.
  2. Better understanding of the pathophysiological processes affecting the AD brain and in particular early or preclinical stages of AD such as MCI, using tissue, cell culture and animal models of ageing and disease.


Administrative Officers

PhD Students

  • Fatemeh Khorshidi
  • Yue Liu
  • Marina Ulanova
  • Gurjeet Virk
  • Matthew Wong